Pfizer announced that Ibrance, its treatment for advanced cancer demonstrated impressive results during the late-stage trial, which was stopped early because of its efficacy.
According to the company, the Phase 3 PALOMA-3 trial from Ibrance met its primary endpoint. The treatment demonstrated improvement in progression-free survival (PFS) for the combination of Ibrance plus fulvestrant in women with advanced breast cancer.
Bonhoeffer Fund's performance update for the month ended July 31, 2022. Q2 2022 hedge fund letters, conferences and more The Bonhoeffer Fund returned 3.5% net of fees in July, for a year-to-date return of -15.8%. Bonhoeffer Fund, LP, is a value-oriented private investment partnership for . . . SORRY! This content is exclusively for Read More
The patients in the trial have breast cancer classified as estrogen-receptor positive, human epidermal g